Real-life second-line epirubicin-paclitaxel regimen as treatment of relapsed small-cell lung cancer: EpiTax study.

Josselin Annic,Hélène Babey,Romain Corre,Renaud Descourt,Gilles Quéré,Emmanuelle Renaud, Mickaël Lambert,Pierre Le Noac'h,Estelle Dhamelincourt,Jessica Nguyen, Alicia Vu,Vincent Bourbonne,Gilles Robinet,Margaux Geier

Cancer medicine（2022）

引用 2|浏览11

暂无评分

摘要

Epirubicin-paclitaxel association highlighted promising efficacy with PFS and OS of 11 and 23 weeks, respectively, ORR of 34.5%, and a tolerable safety profile. This doublet could represent another valuable therapeutic option for ES-SCLC patients treated in the second line and beyond.

查看译文

关键词

cerebral efficacy,epirubicin,paclitaxel,real life,small-cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要